Lyme disease update: Current approach to early, disseminated, and late disease

Daniel Wallace Rahn, Michael W. Felz

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

A rational approach to diagnosis and treatment of Lyme disease requires an understanding of the endemic range of the tick vectors for B burgdorferi, the epidemiologic risk factors, and the spectrum of clinical manifestations. A two-step approach to serologic testing (ELISA followed by Western blot analysis of positive or equivocal results) can be useful if the pretest likelihood of Lyme disease is higher than 20%. Consideration should be given to the possibility of (1) a noninfectious disease with clinical features similar to those of Lyme disease or (2) coinfection with a second tick- transmitted organism. Late Lyme disease must be distinguished by clinical characteristics from fibromyalgia (the commonest source of misdiagnosis in several studies). Antibiotic therapy should be tailored to the extent of disease and limited to 4 weeks in most cases. Human vaccines based on an outer-surface protein from B burgdorferi have been tested in large-scale US clinical trials and may soon be approved for use in persons whose occupational or recreational activities place them at risk for B burgdorferi exposure.

Original languageEnglish (US)
Pages (from-to)51-70
Number of pages20
JournalPostgraduate Medicine
Volume103
Issue number5
DOIs
StatePublished - Jan 1 1998

Fingerprint

Lyme Disease
Ticks
Epidemiologic Factors
Fibromyalgia
Diagnostic Errors
Coinfection
Membrane Proteins
Vaccines
Western Blotting
Enzyme-Linked Immunosorbent Assay
Clinical Trials
Anti-Bacterial Agents
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lyme disease update : Current approach to early, disseminated, and late disease. / Rahn, Daniel Wallace; Felz, Michael W.

In: Postgraduate Medicine, Vol. 103, No. 5, 01.01.1998, p. 51-70.

Research output: Contribution to journalReview article

@article{83b2c3e1dd4940bb9d8a9528f7ff83da,
title = "Lyme disease update: Current approach to early, disseminated, and late disease",
abstract = "A rational approach to diagnosis and treatment of Lyme disease requires an understanding of the endemic range of the tick vectors for B burgdorferi, the epidemiologic risk factors, and the spectrum of clinical manifestations. A two-step approach to serologic testing (ELISA followed by Western blot analysis of positive or equivocal results) can be useful if the pretest likelihood of Lyme disease is higher than 20{\%}. Consideration should be given to the possibility of (1) a noninfectious disease with clinical features similar to those of Lyme disease or (2) coinfection with a second tick- transmitted organism. Late Lyme disease must be distinguished by clinical characteristics from fibromyalgia (the commonest source of misdiagnosis in several studies). Antibiotic therapy should be tailored to the extent of disease and limited to 4 weeks in most cases. Human vaccines based on an outer-surface protein from B burgdorferi have been tested in large-scale US clinical trials and may soon be approved for use in persons whose occupational or recreational activities place them at risk for B burgdorferi exposure.",
author = "Rahn, {Daniel Wallace} and Felz, {Michael W.}",
year = "1998",
month = "1",
day = "1",
doi = "10.3810/pgm.1998.05.482",
language = "English (US)",
volume = "103",
pages = "51--70",
journal = "Postgraduate Medicine",
issn = "0032-5481",
publisher = "Medquest Communications LLC",
number = "5",

}

TY - JOUR

T1 - Lyme disease update

T2 - Current approach to early, disseminated, and late disease

AU - Rahn, Daniel Wallace

AU - Felz, Michael W.

PY - 1998/1/1

Y1 - 1998/1/1

N2 - A rational approach to diagnosis and treatment of Lyme disease requires an understanding of the endemic range of the tick vectors for B burgdorferi, the epidemiologic risk factors, and the spectrum of clinical manifestations. A two-step approach to serologic testing (ELISA followed by Western blot analysis of positive or equivocal results) can be useful if the pretest likelihood of Lyme disease is higher than 20%. Consideration should be given to the possibility of (1) a noninfectious disease with clinical features similar to those of Lyme disease or (2) coinfection with a second tick- transmitted organism. Late Lyme disease must be distinguished by clinical characteristics from fibromyalgia (the commonest source of misdiagnosis in several studies). Antibiotic therapy should be tailored to the extent of disease and limited to 4 weeks in most cases. Human vaccines based on an outer-surface protein from B burgdorferi have been tested in large-scale US clinical trials and may soon be approved for use in persons whose occupational or recreational activities place them at risk for B burgdorferi exposure.

AB - A rational approach to diagnosis and treatment of Lyme disease requires an understanding of the endemic range of the tick vectors for B burgdorferi, the epidemiologic risk factors, and the spectrum of clinical manifestations. A two-step approach to serologic testing (ELISA followed by Western blot analysis of positive or equivocal results) can be useful if the pretest likelihood of Lyme disease is higher than 20%. Consideration should be given to the possibility of (1) a noninfectious disease with clinical features similar to those of Lyme disease or (2) coinfection with a second tick- transmitted organism. Late Lyme disease must be distinguished by clinical characteristics from fibromyalgia (the commonest source of misdiagnosis in several studies). Antibiotic therapy should be tailored to the extent of disease and limited to 4 weeks in most cases. Human vaccines based on an outer-surface protein from B burgdorferi have been tested in large-scale US clinical trials and may soon be approved for use in persons whose occupational or recreational activities place them at risk for B burgdorferi exposure.

UR - http://www.scopus.com/inward/record.url?scp=0031801858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031801858&partnerID=8YFLogxK

U2 - 10.3810/pgm.1998.05.482

DO - 10.3810/pgm.1998.05.482

M3 - Review article

C2 - 9590986

AN - SCOPUS:0031801858

VL - 103

SP - 51

EP - 70

JO - Postgraduate Medicine

JF - Postgraduate Medicine

SN - 0032-5481

IS - 5

ER -